使用联合分析法评估良性前列腺增生治疗中的患者偏好
本研究通过在线横断面调查对1235名招募参与者中的812名完成者进行平衡选择联合分析,量化良性前列腺增生患者对疗效、恢复难度、并发症风险(Clavien-Dindo 2级及以上)和射精功能障碍风险的偏好。并发症风险是最重要的属性,其次为疗效、恢复难度和射精功能障碍风险;年龄亚组分析显示不同年龄段偏好存在差异,强调个体化诊疗的必要性。
要点
- 并发症风险是良性前列腺增生患者治疗决策中最重要的属性。
- 射精功能障碍风险对患者治疗选择的影响最小。
- 年龄<38岁参与者将疗效(31%)视为最高相对重要性,年龄>67岁参与者将并发症风险(47%)视为最高相对重要性。
核心结论
- 男性重视将并发症风险降至最低的良性前列腺增生治疗方法,而射精功能障碍的影响最小。
- 年龄亚组间结果的差异强调需要个体化诊疗以最大化患者满意度。
研究设计与样本
- 横断面在线调查研究,通过researchmatch.org招募参与者,要求参与者在理论良性前列腺增生治疗之间进行平衡的、基于选择的联合分析。
- 共招募1235名参与者,812名(66%)完成研究;国际前列腺症状评分中位数为6(IQR 3-12),年龄中位数为56岁(IQR 38-67)。
主要发现
- 并发症风险是最重要的属性,其次为疗效、恢复难度和射精功能障碍风险。
- 在年龄四分位亚组分析中,年龄<38岁参与者将疗效(31%)视为最高相对重要性,年龄>67岁参与者将并发症风险(47%)视为最高相对重要性。
临床怎么用
- 美国泌尿外科学会指南敦促泌尿外科医生在推荐良性前列腺增生治疗时考虑患者偏好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify benign prostatic hyperplasia (BPH) patient preferences to promote guidelines-compliant, patient-centered care. Discordance between patient and urologist priorities for the treatment of BPH hinders patient-centered care. Physician assumptions regarding patient preferences lead to dissatisfied patients; a poor outcome in any quality of life surgery. American Urologic Association guidelines urge urologists to consider patient preferences when recommending a BPH treatment. METHODS: In this cross-sectional, online survey study using researchmatch.org, participants were required to decide between theoretical BPH treatments in a balanced, choice-based conjoint analysis. The treatments had varying levels of four attributes: efficacy, recovery difficulty, risk of complications (Clavien-Dindo 2+), and risk of de novo ejaculatory dysfunction. Demographic information and International Prostate Symptom Score were collected and analyzed using comparative statistics. Each attribute was analyzed using a conditional logit model, and attribute importance (range in utility between attribute-levels) was calculated. RESULTS: Out of 1235 recruited participants, 812 (66%) completed the study. Median International Prostate Symptom Score and age was 6 (IQR 3-12) and 56 (IQR 38-67), respectively. Complication risk was the most important attribute, followed by efficacy, recovery difficulty, and risk of ejaculatory dysfunction. In a subgroup analysis of age quartiles, participants age <38 and >67 held efficacy (31%) and complication risk (47%) to the highest relative importance, respectively. CONCLUSION: Males valued BPH treatments that minimize complication risks, while ejaculatory dysfunction was least impactful. Variation in results between age subgroups emphasizes the need for individualized care to maximize patient satisfaction.
引用
- Huffman PJ, Yin E, Cohen AJ, et al. Evaluating Patient Preferences in Benign Prostatic Hyperplasia Treatment Using Conjoint Analysis. Urology. 2022. PMID: 35063462. doi:10.1016/j.urology.2022.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。